Drugs / EGFRvIII-CAR T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05063682 | May 2020 → Oct 2023 | glioblastoma | Chembrain LTD | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFRvIII-CAR T Cells | “The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma.” NCT05063682 ↗ |
| Action | Deplete | “recognize and destroy brain tumor cells” NCT05063682 ↗ |
| Modality | Cell therapy | “Immune cells can be genetically modified to destroy brain tumor cells in the laboratory.” NCT05063682 ↗ |
| Route | Other | “intracerebroventricular over 15 minutes on day 1” NCT05063682 ↗ |
| Target | EGFR | “A Phase 1 Study to Evaluate EGFRvIII -Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma” NCT05063682 ↗ |